Posts

Sage Therapeutics and partner Biogen shared news that their Phase III Skylark study has yielded promising results for women suffering from severe postpartum depression (PPD).

On Tuesday morning, Eledon Pharmaceuticals announced positive topline results from the company’s Phase IIa clinical trial evaluating tegoprubart in patients with amyotrophic lateral sclerosis (ALS).

Genentech, a member of the Roche group, announced new data on Thursday related to the company’s investigational CD20xCD3 T-cell engaging bispecific antibody glofitamab, which is intended to treat relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

Janssen Pharmaceutical shared positive updates from ongoing trials on candidate therapies for Crohn’s disease (CD) and ulcerative colitis (UC) at Digestive Disease Week in San Diego, California.

The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) are combining their efforts to increase racial and ethnic diversity in clinical trials.

After announcing plans to explore strategic alternatives less than a month ago, Genocea Biosciences is shutting down operations.

Imugene and City of Hope announced this week that the first patient has begun treatment in a revolutionary Phase I clinical trial, investigating the safety and efficacy of CF33-hNIS (Vaxinia), a cancer-killing virus, in adults with metastatic or advanced tumors. 

Regeneron Pharmaceuticals shared positive results from the company’s Phase III trial of a candidate drug for children with homozygous familial hypercholesterolemia (HoFH), a rare, life-threatening condition characterized by elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD.

Biohaven Pharmaceutical said on May 23 the company’s experimental drug for patients with spinocerebellar ataxia, a genetic disease that affects the nervous system, failed to meet the main goal of a late-stage study.

Ocugen Inc. said on May 23 the U.S. drug regulator has lifted the clinical hold on a mid-to-late stage trial of the COVID-19 vaccine being developed by the company’s Indian partner Bharat Biotech.